TICKERNERD
Menu
CRDLCRDLHealthcare · Drug Manufacturers - Specialty & Generic

CRDL Stock Forecast: Cardiol Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$1.32
+0.76% on the day

The 6 Wall Street analysts covering Cardiol Therapeutics, Inc. hold a median 12-month price target of $8.87 — +571.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 6 Oct 2026 — in the upper half.

Market cap
$160.4M
Ticker Nerd rank
54 / 100
Median analyst target
$8.87
Analysts covering
6
Revenue$0.0
Operating income−$7.9M
Net income−$6.1M
Free cash flow−$4.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−20.5%
1M
−40.0%
YTD
+38.4%
1Y
+24.5%
From 52W high
−42.2%
From 52W low
+42.5%
$0.93
$2.29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRDL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cardiol Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
75
Momentum
75
Growth
71
Size
70
Accruals
53
Value
52
Revisions
47
Issuance
36
Quality
16

Volatility (75): The share price has been relatively steady.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRDL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRDL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26CRDLHigh $10.70Median $8.87Low $4.96

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $4.96Median $8.87High $10.70

The green dot is the last close — the median target sits +571.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Sept 2026HC Wainwright & Co.ReiteratesBuy$9.00
17 Aug 2026Canaccord GenuityMaintainsBuy$8.00 → $10
17 Aug 2026Canaccord GenuityMaintainsBuy—
14 July 2026HC Wainwright & Co.ReiteratesBuy$9.00
14 July 2026HC Wainwright & Co.ReiteratesBuy—
6 Apr 2026Canaccord GenuityMaintainsBuy—
6 Apr 2026Canaccord GenuityMaintainsBuy$8.00
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
1 Dec 2025HC Wainwright & Co.ReiteratesBuy—
2 June 2025HC Wainwright & Co.InitiatesBuy—
16 Apr 2025HC Wainwright & Co.ReiteratesBuy—
7 Apr 2025HC Wainwright & Co.ReiteratesBuy—
24 Feb 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
26 June 2024Roth MKMInitiatesBuy—
14 June 2024HC Wainwright & Co.ReiteratesBuy—
7 June 2024HC Wainwright & Co.ReiteratesBuy—
23 May 2024Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRDL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRDL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Cardiol Therapeutics, Inc. returned +24.5% against +17.7% for the S&P 500, dividends included.

CRDL vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Jan 26Apr 26Jul 26Oct 26CRDLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRDL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Cardiol Therapeutics, Inc. (CRDL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.4×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
9.1×

Cheaper than 10% of US stocks

EV / EBITDA
−3.6×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−190.2%

Higher than 8% of US stocks

Return on assets
−90.9%

Higher than 3% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cardiol Therapeutics, Inc. (CRDL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cardiol Therapeutics, Inc. has a market value of $160.4M and an enterprise value of $90.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$34.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$24.1M.

  • Shares outstanding: 115.3M.

  • Trailing P/E: −3.4×; forward P/E: −5.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cardiol Therapeutics, Inc. employs 18 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

CRDL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
CRDLCardiol Therapeutics, Inc.$160.4M
54
ADCTADC Therapeutics SA$157.3M
81
DERMJourney Medical Corp.$168.4M
69
ORGOOrganogenesis Holdings, Inc.$170.1M
41
OGIOrganigram Global, Inc.$137.6M
43
BGMBGM Group Ltd.$128.9M
39
AKBAAkebia Therapeutics, Inc.$235.3M
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cardiol Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRDL news & analysis

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

PRNewsWire · 23 Sept 2026positive

Cardiol Therapeutics announced it achieved the original 110-patient enrollment target for its Phase III MAVERIC trial ahead of its end-of-September guidance. The MAVERIC Steering Committee recommended expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx's potential to reduce recurrence risk.

Why it matters — CRDL watchers would care because the trial reached its milestone ahead of schedule and is being expanded to strengthen the efficacy assessment of CardiolRx.

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

PRNewsWire · 16 Sept 2026positive

Cardiol Therapeutics announced the exercise of warrants generating over USD $7 million in proceeds, which will strengthen its balance sheet ahead of the pivotal Phase III MAVERIC trial readout in recurrent pericarditis and extend its cash runway into H1 2028.

Why it matters — The additional funding bolsters the company's financial position and cash runway as it approaches a key Phase III data readout in recurrent pericarditis.

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

Zacks Investment Research · 14 Sept 2026positive

Zacks Investment Research published a list of five small drug stocks it sees as poised to benefit from a biotech recovery, including Cardiol Therapeutics (CRDL), citing catalysts and differentiated pipelines. The piece notes that CRDL and the other named companies could offer significant upside as biotech sentiment improves.

Why it matters — The item highlights CRDL among a select group of small-cap drug stocks that analysts see as well positioned as biotech sentiment improves, giving CRDL watchers context on the company's perceived catalyst-driven upside.

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

PRNewsWire · 10 Sept 2026neutral

Cardiol Therapeutics announced it has filed a preliminary short form base shelf prospectus with Canadian securities regulators, along with a corresponding registration statement on Form F-10 with the SEC, for a proposed US$150 million base shelf offering under the U.S./Canada Multijurisdictional Disclosure System.

Why it matters — The shelf prospectus filing gives Cardiol the regulatory framework to potentially raise up to US$150 million in future capital, which is relevant for investors tracking the company's financing capacity.

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 9 Sept 2026neutral

Cardiol Therapeutics announced it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company, which develops anti-inflammatory and anti-fibrotic therapies for heart disease, made the announcement on September 9, 2026.

Why it matters — The conference appearance gives Cardiol Therapeutics a platform to present its late-stage heart disease therapies to investors and industry participants.

FAQ

Frequently asked questions about CRDL stock

What is the CRDL stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Cardiol Therapeutics, Inc. have a median 12-month price target of $8.87, with estimates ranging from $4.96 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRDL stock a buy right now?

Of the 6 analysts covering Cardiol Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardiol Therapeutics, Inc. 54 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRDL?

As at 6 Oct 2026, Cardiol Therapeutics, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (75 of 100).

Will CRDL stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +571.9% from the last close, and Ticker Nerd's factor model ranks Cardiol Therapeutics, Inc. 54 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRDL stock forecast for 2030?

No analyst covering Cardiol Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRDL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.96 to $11 over the next 12 months.

How has CRDL stock performed over the past year?

Cardiol Therapeutics, Inc. returned +24.5% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cardiol Therapeutics, Inc. do?

Cardiol Therapeutics Inc. Class A Common Shares represents an equity interest in Cardiol Therapeutics, a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease.

What is the latest news on CRDL?

The most recent item we track (PRNewsWire, 23 Sept 2026): "Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy". Cardiol Therapeutics announced it achieved the original 110-patient enrollment target for its Phase III MAVERIC trial ahead of its end-of-September guidance. The MAVERIC Steering Committee recommended expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx's potential to reduce recurrence risk.

Company

About Cardiol Therapeutics, Inc.

Cardiol Therapeutics Inc. Class A Common Shares represents an equity interest in Cardiol Therapeutics, a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. The company’s current work centers on CardiolRx, a pharmaceutically manufactured oral cannabidiol formulation in clinical development for cardiovascular indications, including inflammatory heart conditions. Cardiol Therapeutics also advances related formulations and programs aimed at addressing the biological pathways involved in cardiac inflammation and fibrosis. Its business is concentrated in the biotechnology and pharmaceutical segments of the healthcare market, where it contributes to the development of specialized therapies for serious heart disorders. Based in Oakville, Ontario, Cardiol Therapeutics is positioned as a research-driven company with a narrow therapeutic focus on heart disease treatment.

CEO Mr. David G. Elsley MBA · 18 employees · Canada · https://www.cardiolrx.com